INT183888

Context Info Confidence 0.49 First Reported 2005 Last Reported 2009 Negated 0 Speculated 0 Reported most in Body Documents 6 Total Number 6 Disease Relevance 1.62 Pain Relevance 0.08

nucleus (PAF1)

Anatomy Link Frequency HPAF-II 1 BxPC-3 1 PAF1 (Homo sapiens)

Pain Link Frequency Relevance Heat tolerance 7 86.40 Pain 6 33.84 cva 16 19.60 Inflammation 4 13.52 beta blocker 17 5.00 amygdala 8 5.00 medulla 8 5.00 Angina 6 5.00 Chronic pancreatitis 4 5.00 fibrosis 2 5.00

Disease Link Frequency Relevance Heat Adenocarcinoma 102 98.52 Death 187 94.00 Heart Rate Under Development 37 84.08 Arrhythmia Under Development 21 81.28 Polycystic Ovary Syndrome 3 57.16 Arrhythmias 2 Under Development 34 53.40 Emergencies 21 50.00 Pancreatic Cancer 14 50.00 Pain 6 33.84 Cv General 3 Under Development 12 19.60

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Expression of cav-1 was increased 3.1-fold in the HPAF-II/dnRhoC cells compared with the parental HPAF-II and vector control cells.

Positive_regulation (increased) of HPAF in HPAF-II

1) Confidence 0.49 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.18 Pain Relevance 0

Treatment with SB220025 increased cav-1 expression dramatically in the HPAF-II and slightly in the BxPC-3 cells, implying a reciprocal relationship between cav-1 expression and p38 activation.

Positive_regulation (increased) of HPAF in BxPC-3

2) Confidence 0.45 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.30 Pain Relevance 0

The 89 PD2i-rejected patients, of the 819 patients with complete data (10.86%), were rejected by both the Randomized Phase Surrogate Test (inverse Fourier with random phases) and the %N Test (% accepted PD2i/total PD2i).

Positive_regulation (accepted) of PD2i

3) Confidence 0.32 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 0.30 Pain Relevance 0

These two PD2i patterns each indicate PD2i ?

Positive_regulation (indicate) of PD2i

4) Confidence 0.32 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 0.42 Pain Relevance 0

The 89 PD2i-rejected patients, of the 819 patients with complete data (10.86%), were rejected by both the Randomized Phase Surrogate Test (inverse Fourier with random phases) and the %N Test (% accepted PD2i/total PD2i).

Positive_regulation (accepted) of PD2i

5) Confidence 0.32 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 0.30 Pain Relevance 0

For values of PD2i that lie in the transition zone between 1.6 and 1.4 (the cut-point, ROC area = 0.91)16 very small amounts of low-level noise can falsely increase low PD2i’s into this region; if data files had such transition zone PD2i scores, then a transition zone algorithm (TZA) was applied: if the mean PD2i was highly reduced from normal with >75% of the PD2i’s being below 3.0, then 0.2 degrees of freedom (dimension) was subtracted from each PD2i value.

Positive_regulation (increase) of PD2i

6) Confidence 0.02 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731023 Disease Relevance 0.11 Pain Relevance 0.08

General Comments

This test has worked.